Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAGETEX Photodynamic Therapy in Vulvar Extra-Mammary Paget's Disease
2024-514093-41-00Phase 2Authorised
- Sponsor
- CHU de Lille
- Start
- Aug 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methyl aminolevulinate in Extramammary Paget disease of the vulva (EMPDV), sponsored by CHU de Lille. Primary endpoint: Disease control rate at 3 months (investigator-assessed). Planned start Aug 2019; status: authorised.
02
Drugs
methyl aminolevulinate
03
Conditions
Extramammary Paget disease of the vulva (EMPDV)
Beyond the preview
Go deeper on 2024-514093-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514093-41-00.